{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T04:09:43Z","timestamp":1790914183666,"version":"4.1.0"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,1,25]],"date-time":"2020-01-25T00:00:00Z","timestamp":1579910400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,1,25]],"date-time":"2020-01-25T00:00:00Z","timestamp":1579910400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Netherlands Cardio Vascular Research Initiative","award":["DHF 2012B001"],"award-info":[{"award-number":["DHF 2012B001"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Health Econ"],"published-print":{"date-parts":[[2020,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objectives<\/jats:title><jats:p>Aortic valve disease is the most frequent indication for heart valve replacement with the highest prevalence in elderly. Tissue-engineered heart valves (TEHV) are foreseen to have important advantages over currently used bioprosthetic heart valve substitutes, most importantly reducing valve degeneration with subsequent reduction of re-intervention. We performed early Health Technology Assessment of hypothetical TEHV in elderly patients (\u2265\u200970\u00a0years) requiring surgical (SAVR) or transcatheter aortic valve implantation (TAVI) to assess the potential of TEHV and to inform future development decisions.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Using a patient-level simulation model, the potential cost-effectiveness of TEHV compared with bioprostheses was predicted from a societal perspective. Anticipated, but currently hypothetical improvements in performance of TEHV, divided in durability, thrombogenicity, and infection resistance, were explored in scenario analyses to estimate quality-adjusted life-year (QALY) gain, cost reduction, headroom, and budget impact.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Durability of TEHV had the highest impact on QALY gain and costs, followed by infection resistance. Improved TEHV performance (\u2212\u200950% prosthetic valve-related events) resulted in lifetime QALY gains of 0.131 and 0.043, lifetime cost reductions of \u20ac639 and \u20ac368, translating to headrooms of \u20ac3255 and \u20ac2498 per hypothetical TEHV compared to SAVR and TAVI, respectively. National savings in the first decade after implementation varied between \u20ac2.8 and \u20ac11.2 million (SAVR) and \u20ac3.2\u2013\u20ac12.8 million (TAVI) for TEHV substitution rates of 25\u2013100%.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Despite the relatively short life expectancy of elderly patients undergoing SAVR\/TAVI, hypothetical TEHV are predicted to be cost-effective compared to bioprostheses, commercially viable and result in national cost savings when biomedical engineers succeed in realising improved durability and\/or infection resistance of TEHV.<\/jats:p><\/jats:sec>","DOI":"10.1007\/s10198-020-01159-y","type":"journal-article","created":{"date-parts":[[2020,1,25]],"date-time":"2020-01-25T17:02:16Z","timestamp":1579971736000},"page":"557-572","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Early cost-utility analysis of tissue-engineered heart valves compared to bioprostheses in the aortic position in elderly patients"],"prefix":"10.1007","volume":"21","author":[{"given":"Simone A.","family":"Huygens","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isaac Corro","family":"Ramos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlijn V. C.","family":"Bouten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jolanda","family":"Kluin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shih Ting","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary L.","family":"Grunkemeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna J. M.","family":"Takkenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maureen P. M. H.","family":"Rutten-van M\u00f6lken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,25]]},"reference":[{"key":"1159_CR1","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/S0195-668X(03)00201-X","volume":"24","author":"B Iung","year":"2003","unstructured":"Iung, B., Baron, G., Butchart, E.G., et al.: A prospective survey of patients with valvular heart disease in Europe: the Euro heart survey on valvular heart disease. Eur. Heart J. 24, 1231\u20131243 (2003)","journal-title":"Eur. Heart J."},{"key":"1159_CR2","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/S0140-6736(06)69208-8","volume":"368","author":"VT Nkomo","year":"2006","unstructured":"Nkomo, V.T., Gardin, J.M., Skelton, T.N., et al.: Burden of valvular heart diseases: a population-based study. The Lancet 368, 1005\u20131011 (2006)","journal-title":"The Lancet"},{"key":"1159_CR3","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1093\/eurheartj\/ehx391","volume":"38","author":"H Baumgartner","year":"2017","unstructured":"Baumgartner, H., Falk, V., Bax, J.J., et al.: 2017 ESC\/EACTS guidelines for the management of valvular heart disease. Eur. Heart J. 38, 2739\u20132791 (2017)","journal-title":"Eur. Heart J."},{"key":"1159_CR4","doi-asserted-by":"crossref","first-page":"e000672","DOI":"10.1136\/openhrt-2017-000672","volume":"5","author":"SA Huygens","year":"2018","unstructured":"Huygens, S.A., Goossens, L.M.A., van Erkelens, J.A., et al.: How much does a heart valve implantation cost and what are the health care costs afterwards? Open Heart 5, e000672 (2018)","journal-title":"Open Heart"},{"key":"1159_CR5","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1093\/eurheartj\/ehy107","volume":"28","author":"AP Durko","year":"2018","unstructured":"Durko, A.P., Osnabrugge, R.L., Van Mieghem, N.M., et al.: Annual number of candidates for transcatheter aortic valve implantation per country: current estimates and future projections. Eur. Heart J. 28, 2635\u20132642 (2018)","journal-title":"Eur. Heart J."},{"key":"1159_CR6","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/ncpcardio0112","volume":"2","author":"MH Yacoub","year":"2005","unstructured":"Yacoub, M.H., Takkenberg, J.J.M.: Will heart valve tissue engineering change the world? Nat. Clin. Pract. Cardiovasc. Med. 2, 60\u201361 (2005)","journal-title":"Nat. Clin. Pract. Cardiovasc. Med."},{"key":"1159_CR7","first-page":"72","volume":"10","author":"A Sokoloff","year":"2018","unstructured":"Sokoloff, A., Durand, E., Avinee, G., et al.: Long-term assessment of durability of transcatheter aortic valves. Experience from the pioneer center. Arch. Cardiovasc. Dis. Suppl. 10, 72 (2018)","journal-title":"Arch. Cardiovasc. Dis. Suppl."},{"key":"1159_CR8","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1016\/j.jtcvs.2018.10.040","volume":"157","author":"SA Huygens","year":"2018","unstructured":"Huygens, S.A., Etnel, J.R., Hanif, M., et al.: Bioprosthetic aortic valve replacement in elderly patients: meta-analysis and microsimulation. J. Thorac. Cardiovasc. Surg. 157, 2189 (2018)","journal-title":"J. Thorac. Cardiovasc. Surg."},{"key":"1159_CR9","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/s41536-017-0023-2","volume":"2","author":"TB Wissing","year":"2017","unstructured":"Wissing, T.B., Bonito, V., Bouten, C.V., et al.: Biomaterial-driven in situ cardiovascular tissue engineering\u2014a multi-disciplinary perspective. NPJ Regen. Med. 2, 18 (2017)","journal-title":"NPJ Regen. Med."},{"key":"1159_CR10","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.biomaterials.2017.02.007","volume":"125","author":"J Kluin","year":"2017","unstructured":"Kluin, J., Talacua, H., Smits, A.I., et al.: In situ heart valve tissue engineering using a bioresorbable elastomeric implant\u2013from material design to 12\u00a0months follow-up in sheep. Biomaterials 125, 101\u2013117 (2017)","journal-title":"Biomaterials"},{"key":"1159_CR11","doi-asserted-by":"crossref","first-page":"54","DOI":"10.3389\/fcvm.2018.00054","volume":"5","author":"CV Bouten","year":"2018","unstructured":"Bouten, C.V., Smits, A., Baaijens, F.: Can we grow valves inside the heart? Perspective on material-based in situ heart valve tissue engineering. Front. Cardiovasc. Med. 5, 54 (2018)","journal-title":"Front. Cardiovasc. Med."},{"key":"1159_CR12","unstructured":"Thierry, B.L.C., Kim, A., Shatalov, K., Makarenko, V., Cox, M., Svanidze, O.: Polymeric bioabsorbable vascular graft in modified Fontan procedure - two-year follow-up. In: 7th World Congress of Pediatric Cardiology & Cardiac Surgery (WCPCCS). Barcelona, 2017"},{"key":"1159_CR13","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.jval.2013.02.002","volume":"16","author":"DDM Husereau","year":"2013","unstructured":"Husereau, D.D.M., Petrou, S., et al.: Consolidated health economic evaluation reporting standards (CHEERS)\u2014explanation and elaboration: a report of the ISPOR health economic evaluations publication guidelines good reporting practices task force. Value Health 16, 231\u2013250 (2013)","journal-title":"Value Health"},{"key":"1159_CR14","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.jval.2012.06.014","volume":"15","author":"U Siebert","year":"2012","unstructured":"Siebert, U., Alagoz, O., Bayoumi, A.M., et al.: State-transition modeling: a report of the ISPOR-SMDM modeling good research practices task force-3. Value Health 15, 812\u2013820 (2012)","journal-title":"Value Health"},{"key":"1159_CR15","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1177\/0272989X12455462","volume":"32","author":"J Karnon","year":"2012","unstructured":"Karnon, J., Stahl, J., Brennan, A., et al.: Modeling using discrete event simulation a report of the ISPOR-SMDM modeling good research practices task force\u20134. Med. Decis. Mak. 32, 701\u2013711 (2012)","journal-title":"Med. Decis. Mak."},{"key":"1159_CR16","doi-asserted-by":"crossref","first-page":"e000500","DOI":"10.1136\/openhrt-2016-000500","volume":"3","author":"SA Huygens","year":"2016","unstructured":"Huygens, S.A., Rutten-van M\u00f6lken, M.P.M.H., Bekkers, J.A., et al.: Conceptual model for early health technology assessment of current and novel heart valve interventions. Open Heart 3, e000500 (2016)","journal-title":"Open Heart"},{"key":"1159_CR17","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.ejcts.2007.12.055","volume":"33","author":"CW Akins","year":"2008","unstructured":"Akins, C.W., Miller, D.C., Turina, M.I., et al.: Guidelines for reporting mortality and morbidity after cardiac valve interventions. Eur. J. Cardiothorac. Surg. 33, 523\u2013528 (2008)","journal-title":"Eur. J. Cardiothorac. Surg."},{"key":"1159_CR18","unstructured":"Centraal Bureau voor de Statistiek (CBS). Overlevingskansen; geslacht, leeftijd. Centraal Bureau voor de Statistiek (CBS) (2016)"},{"key":"1159_CR19","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S0735-1097(99)00584-7","volume":"35","author":"P Kvidal","year":"2000","unstructured":"Kvidal, P., Bergstr\u00f6m, R., H\u00f6rte, L.-G., et al.: Observed and relative survival after aortic valve replacement. J. Am. Coll. Cardiol. 35, 747\u2013756 (2000)","journal-title":"J. Am. Coll. Cardiol."},{"key":"1159_CR20","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.4244\/EIJY15M09_11","volume":"11","author":"H Eggebrecht","year":"2015","unstructured":"Eggebrecht, H., Mehta, R.H.: Transcatheter aortic valve implantation (TAVI) in Germany 2008\u20132014: On its way to standard therapy for aortic valve stenosis in the elderly? EuroIntervention 11, 1029 (2015)","journal-title":"EuroIntervention"},{"key":"1159_CR21","doi-asserted-by":"crossref","first-page":"334","DOI":"10.7326\/M16-0060","volume":"165","author":"G Gargiulo","year":"2016","unstructured":"Gargiulo, G., Sannino, A., Capodanno, D., et al.: Transcatheter aortic valve implantation versus surgical aortic valve replacement: a systematic review and meta-analysis. Ann. Intern. Med. 165, 334\u2013344 (2016)","journal-title":"Ann. Intern. Med."},{"key":"1159_CR22","unstructured":"Organisation for Economic Co-operation and Development (OECD). Expenditure by disease, age and gender under the System of Health Accounts (SHA) Framework : Current health spending by age. Organisation for Economic Co-operation and Development (OECD) (2011)"},{"issue":"4","key":"1159_CR23","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1093\/ejcts\/ezy382","volume":"55","author":"SA Huygens","year":"2018","unstructured":"Huygens, S.A., van der Kley, F., Bekkers, A.J.J.C., et al.: Beyond the clinical impact of aortic and pulmonary valve implantation: health-related quality of life, informal care and productivity. Eur. J. Cardiothorac. Surg. 55(4), 751\u2013759 (2019). https:\/\/doi.org\/10.1093\/ejcts\/ezy382","journal-title":"Eur. J. Cardiothorac. Surg."},{"key":"1159_CR24","doi-asserted-by":"crossref","first-page":"e008220","DOI":"10.1136\/bmjopen-2015-008220","volume":"5","author":"M Van Eeden","year":"2015","unstructured":"Van Eeden, M., van Heugten, C., van Mastrigt, G., et al.: The burden of stroke in The Netherlands: estimating quality of life and costs for 1\u00a0year poststroke. BMJ Open 5, e008220 (2015)","journal-title":"BMJ Open"},{"key":"1159_CR25","unstructured":"Huygens, S.A., van der Kley, F., Bekkers, J.A., et al.: Beyond the clinical impact of heart valve implantations - health-related quality of life, informal care, and productivity (2018). (Submitted)"},{"key":"1159_CR26","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.jval.2016.01.003","volume":"19","author":"MM Versteegh","year":"2016","unstructured":"Versteegh, M.M., Vermeulen, K.M., Evers, S.M.A.A., et al.: Dutch tariff for the five-level version of EQ-5D. Value Health 19, 343 (2016)","journal-title":"Value Health"},{"key":"1159_CR27","volume-title":"Richtlijn voor het uitvoeren van economische evaluaties in de gezondheidszorg","author":"N Zorginstituut","year":"2015","unstructured":"Zorginstituut, N.: Richtlijn voor het uitvoeren van economische evaluaties in de gezondheidszorg. Zorginstituut Nederland, Diemen (2015)"},{"key":"1159_CR28","unstructured":"Zwaap, J., Knies, S., van der Meijden, C., et al.: Kosteneffectiviteit in de praktijk. Zorginstituut Nederland (2015)"},{"key":"1159_CR29","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.2165\/00019053-200422170-00001","volume":"22","author":"EA Stolk","year":"2004","unstructured":"Stolk, E.A., van Donselaar, G., Brouwer, W.B.F., et al.: Reconciliation of economic concerns and health policy. Pharmacoeconomics 22, 1097\u20131107 (2004)","journal-title":"Pharmacoeconomics"},{"key":"1159_CR30","unstructured":"Versteegh M.M.: The iMTA Disease burden calculator. Software version 1.3. In: Institute of Medical Technology Assessment (iMTA) EUR (2016)"},{"key":"1159_CR31","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780198526629.001.0001","volume-title":"Decision modelling for health economic evaluation","author":"A Briggs","year":"2006","unstructured":"Briggs, A., Sculpher, M., Claxton, K.: Decision modelling for health economic evaluation. OUP Oxford, Oxford (2006)"},{"issue":"11","key":"1159_CR32","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1007\/s40273-019-00844-y","volume":"37","author":"NC B\u00fcy\u00fckkaramikli","year":"2019","unstructured":"B\u00fcy\u00fckkaramikli NC, Rutten-van M\u00f6lken MPMH, Severens JL, Al M.: TECH-VER: A verification checklist to reduce errors in models and improve their credibility. Pharmacoeconomics. 37(11):1391\u20131408. https:\/\/doi.org\/10.1007\/s40273-019-00844-y","journal-title":"Pharmacoeconomics"},{"key":"1159_CR33","first-page":"40","volume":"56","author":"E Arias","year":"2007","unstructured":"Arias, E.: United States life tables, 2004. Natl. Vital Stat. Rep. 56, 40 (2007)","journal-title":"Natl. Vital Stat. Rep."},{"key":"1159_CR34","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1177\/0272989X12454579","volume":"32","author":"DM Eddy","year":"2012","unstructured":"Eddy, D.M., Hollingworth, W., Caro, J.J., et al.: Model transparency and validation a report of the ISPOR-SMDM modeling good research practices task force\u20137. Med. Decis. Mak. 32, 733\u2013743 (2012)","journal-title":"Med. Decis. Mak."},{"key":"1159_CR35","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.jacc.2013.03.074","volume":"62","author":"D Mylotte","year":"2013","unstructured":"Mylotte, D., Osnabrugge, R.L.J., Windecker, S., et al.: Transcatheter aortic valve replacement in Europe: adoption trends and factors influencing device utilization. J. Am. Coll. Cardiol. 62, 210\u2013219 (2013)","journal-title":"J. Am. Coll. Cardiol."},{"key":"1159_CR36","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1080\/17434440.2018.1419865","volume":"15","author":"SE Motta","year":"2018","unstructured":"Motta, S.E., Lintas, V., Fioretta, E.S., et al.: Off-the-shelf tissue engineered heart valves for in situ regeneration: current state, challenges and future directions. Expert Rev. Med. Devices 15, 35\u201345 (2018)","journal-title":"Expert Rev. Med. Devices"},{"key":"1159_CR37","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/j.athoracsur.2018.11.066","volume":"107","author":"SA Huygens","year":"2019","unstructured":"Huygens, S.A., Rutten-van M\u00f6lken, M.P., Noruzi, A., et al.: What is the potential of tissue-engineered pulmonary valves in children? Ann. Thorac. Surg. 107, 1845\u20131853 (2019)","journal-title":"Ann. Thorac. Surg."},{"key":"1159_CR38","doi-asserted-by":"crossref","first-page":"e100563","DOI":"10.1371\/journal.pone.0100563","volume":"9","author":"T-E Tan","year":"2014","unstructured":"Tan, T.-E., Peh, G.S.L., George, B.L., et al.: A cost-minimization analysis of tissue-engineered constructs for corneal endothelial transplantation. PLoS ONE 9, e100563 (2014)","journal-title":"PLoS ONE"},{"key":"1159_CR39","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1017\/S0266462307080051","volume":"24","author":"JB Pietzsch","year":"2008","unstructured":"Pietzsch, J.B., Pat\u00e9-Cornell, M.E.: Early technology assessment of new medical devices. Int. J. Technol. Assess. Health Care 24, 36\u201344 (2008)","journal-title":"Int. J. Technol. Assess. Health Care"},{"key":"1159_CR40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S0266462316000064","volume":"32","author":"LR Buisman","year":"2016","unstructured":"Buisman, L.R., Rutten-van M\u00f6lken, M.P., Postmus, D., et al.: The early bird catches the worm: early cost-effectiveness analysis of new medical tests. Int. J. Technol. Assess. Health Care 32, 1\u20138 (2016)","journal-title":"Int. J. Technol. Assess. Health Care"},{"key":"1159_CR41","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.jacc.2013.04.037","volume":"62","author":"RR Makkar","year":"2013","unstructured":"Makkar, R.R., Jilaihawi, H., Chakravarty, T., et al.: Determinants and outcomes of acute transcatheter valve-in-valve therapy or embolization: a study of multiple valve implants in the US PARTNER trial (placement of AoRTic TraNscathetER valve trial edwards SAPIEN transcatheter heart valve). J. Am. Coll. Cardiol. 62, 418\u2013430 (2013)","journal-title":"J. Am. Coll. Cardiol."},{"key":"1159_CR42","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/S0140-6736(05)67702-1","volume":"366","author":"P Rothwell","year":"2005","unstructured":"Rothwell, P., Coull, A., Silver, L., et al.: Population-based study of event-rate, incidence, case fatality, and mortality for all acute vascular events in all arterial territories (Oxford vascular study). The Lancet 366, 1773\u20131783 (2005)","journal-title":"The Lancet"},{"issue":"881\u201386","key":"1159_CR43","first-page":"e5","volume":"137","author":"MWA van Geldorp","year":"2009","unstructured":"van Geldorp, M.W.A., Eric Jamieson, W.R., Kappetein, A.P., et al.: Patient outcome after aortic valve replacement with a mechanical or biological prosthesis: weighing lifetime anticoagulant-related event risk against reoperation risk. J. Thorac. Cardiovasc. Surg. 137(881\u201386), e5 (2009)","journal-title":"J. Thorac. Cardiovasc. Surg."},{"key":"1159_CR44","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1093\/ehjci\/jex181","volume":"19","author":"A Franzone","year":"2018","unstructured":"Franzone, A., Pilgrim, T., Haynes, A.G., et al.: Transcatheter aortic valve thrombosis: incidence, clinical presentation and long-term outcomes. Eur. Heart J. Cardiovasc. Imag. 19, 398\u2013404 (2018)","journal-title":"Eur. Heart J. Cardiovasc. Imag."},{"key":"1159_CR45","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ijcard.2015.07.022","volume":"199","author":"N Jander","year":"2015","unstructured":"Jander, N., Sommer, H., Pingpoh, C., et al.: The porcine valve type predicts obstructive thrombosis beyond the first three postoperative months in bioprostheses in the aortic position. Int. J. Cardiol. 199, 90\u201395 (2015)","journal-title":"Int. J. Cardiol."},{"key":"1159_CR46","doi-asserted-by":"crossref","first-page":"e001779","DOI":"10.1161\/CIRCINTERVENTIONS.114.001779","volume":"8","author":"A Latib","year":"2015","unstructured":"Latib, A., Naganuma, T., Abdel-Wahab, M., et al.: Treatment and clinical outcomes of transcatheter heart valve thrombosis. Circ. Cardiovasc. Interv. 8, e001779 (2015)","journal-title":"Circ. Cardiovasc. Interv."},{"key":"1159_CR47","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1161\/01.CIR.72.4.753","volume":"72","author":"EH Blackstone","year":"1985","unstructured":"Blackstone, E.H., Kirklin, J.W.: Death and other time-related events after valve replacement. Circulation 72, 753\u2013767 (1985)","journal-title":"Circulation"},{"key":"1159_CR48","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1080\/24748706.2017.1381357","volume":"1","author":"BP Geisler","year":"2017","unstructured":"Geisler, B.P., Huygens, S.A., Reardon, M.J., et al.: Cost-effectiveness and projected survival of self-expanding transcatheter versus surgical aortic valve replacement for high risk patients in a European setting. A Dutch analysis based on the corevalve high-risk trial. Struct. Heart 1, 5 (2017)","journal-title":"Struct. Heart"},{"key":"1159_CR49","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1007\/s00134-014-3373-x","volume":"40","author":"M van Vliet","year":"2014","unstructured":"van Vliet, M., Verburg, I.W., van den Boogaard, M., et al.: Trends in admission prevalence, illness severity and survival of haematological patients treated in Dutch intensive care units. Intensive Care Med. 40, 1275\u20131284 (2014)","journal-title":"Intensive Care Med."},{"key":"1159_CR50","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.jval.2016.10.015","volume":"20","author":"S van der Pol","year":"2017","unstructured":"van der Pol, S., Degener, F., Postma, M.J., et al.: An economic evaluation of sacubitril\/valsartan for heart failure patients in The Netherlands. Value Health 20, 388\u2013396 (2017)","journal-title":"Value Health"},{"issue":"1","key":"1159_CR51","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1161\/CIRCULATIONAHA.114.013748","volume":"131","author":"M Packer","year":"2014","unstructured":"Packer, M., McMurray, J.J., Desai, A.S., et al.: Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. Circulation 131(1), 54\u201361 (2014). https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.114.013748","journal-title":"Circulation"},{"key":"1159_CR52","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","volume":"371","author":"JJV McMurray","year":"2014","unstructured":"McMurray, J.J.V., Packer, M., Desai, A.S., et al.: Angiotensin\u2013neprilysin inhibition versus enalapril in heart failure. N. Engl. J. Med. 371, 993\u20131004 (2014)","journal-title":"N. Engl. J. Med."},{"key":"1159_CR53","unstructured":"Zorginstituut Nederland. Medicijnkosten (2017)"},{"key":"1159_CR54","doi-asserted-by":"crossref","first-page":"e0187477","DOI":"10.1371\/journal.pone.0187477","volume":"12","author":"TA Kanters","year":"2017","unstructured":"Kanters, T.A., Bouwmans, C.A., van der Linden, N., et al.: Update of the Dutch manual for costing studies in health care. PLoS ONE 12, e0187477 (2017)","journal-title":"PLoS ONE"},{"issue":"409\u201318","key":"1159_CR55","first-page":"e1","volume":"170","author":"M \u00d6zkan","year":"2015","unstructured":"\u00d6zkan, M., G\u00fcnd\u00fcz, S., G\u00fcrsoy, O.M., et al.: Ultraslow thrombolytic therapy: a novel strategy in the management of PROsthetic MEchanical valve thrombosis and the prEdictors of outcomE: the ultra-slow PROMETEE trial. Am. Heart J. 170(409\u201318), e1 (2015)","journal-title":"Am. Heart J."},{"key":"1159_CR56","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1016\/S0140-6736(04)16405-2","volume":"363","author":"PM Rothwell","year":"2004","unstructured":"Rothwell, P.M., Coull, A.J., Giles, M.F., et al.: Change in stroke incidence, mortality, case-fatality, severity, and risk factors in Oxfordshire, UK from 1981 to 2004 (Oxford vascular study). The Lancet 363, 1925\u20131933 (2004)","journal-title":"The Lancet"},{"key":"1159_CR57","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1177\/0272989X09349961","volume":"30","author":"O Rivero-Arias","year":"2010","unstructured":"Rivero-Arias, O., Ouellet, M., Gray, A., et al.: Mapping the modified Rankin scale (mRS) measurement into the generic EuroQol (EQ-5D) health outcome. Med. Decis. Mak. 30, 341\u2013354 (2010)","journal-title":"Med. Decis. Mak."},{"key":"1159_CR58","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.ahj.2004.08.037","volume":"150","author":"SD Reed","year":"2005","unstructured":"Reed, S.D., Radeva, J.I., Weinfurt, K.P., et al.: Resource use, costs, and quality of life among patients in the multinational Valsartan in acute myocardial infarction trial (VALIANT). Am. Heart J. 150, 323\u2013329 (2005)","journal-title":"Am. Heart J."},{"key":"1159_CR59","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.jchf.2013.12.003","volume":"2","author":"EF Lewis","year":"2014","unstructured":"Lewis, E.F., Li, Y., Pfeffer, M.A., et al.: Impact of cardiovascular events on change in quality of life and utilities in patients after myocardial infarction: a VALIANT study (valsartan in acute myocardial infarction). JACC Heart Fail. 2, 159\u2013165 (2014)","journal-title":"JACC Heart Fail."},{"key":"1159_CR60","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1161\/01.CIR.89.4.1859","volume":"89","author":"DJ Cohen","year":"1994","unstructured":"Cohen, D.J., Breall, J.A., Ho, K.K., et al.: Evaluating the potential cost-effectiveness of stenting as a treatment for symptomatic single-vessel coronary disease. Use of a decision-analytic model. Circulation 89, 1859\u20131874 (1994)","journal-title":"Circulation"},{"key":"1159_CR61","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jacc.2015.10.034","volume":"67","author":"AP Amin","year":"2016","unstructured":"Amin, A.P., Wang, T.Y., McCoy, L., et al.: Impact of bleeding on quality of life in patients on DAPT: insights from TRANSLATE-ACS. J. Am. Coll. Cardiol. 67, 59\u201365 (2016)","journal-title":"J. Am. Coll. Cardiol."},{"key":"1159_CR62","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s11136-010-9591-y","volume":"19","author":"J Berg","year":"2010","unstructured":"Berg, J., Lindgren, P., Nieuwlaat, R., et al.: Factors determining utility measured with the EQ-5D in patients with atrial fibrillation. Qual. Life Res. 19, 381\u2013390 (2010)","journal-title":"Qual. Life Res."},{"key":"1159_CR63","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.ahj.2008.04.029","volume":"156","author":"JM van Eck","year":"2008","unstructured":"van Eck, J.M., van Hemel, N.M., van den Bos, A., et al.: Predictors of improved quality of life 1\u00a0year after pacemaker implantation. Am. Heart J. 156, 491\u2013497 (2008)","journal-title":"Am. Heart J."},{"key":"1159_CR64","doi-asserted-by":"crossref","first-page":"R250","DOI":"10.1186\/cc13076","volume":"17","author":"S Nisula","year":"2013","unstructured":"Nisula, S., Vaara, S.T., Kaukonen, K.-M., et al.: Six-month survival and quality of life of intensive care patients with acute kidney injury. Crit. Care 17, R250 (2013)","journal-title":"Crit. Care"},{"key":"1159_CR65","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s12955-016-0512-9","volume":"14","author":"K Kaier","year":"2016","unstructured":"Kaier, K., Gutmann, A., Baumbach, H., et al.: Quality of life among elderly patients undergoing transcatheter or surgical aortic valve replacement\u2013a model-based longitudinal data analysis. Health Qual Life Outcomes 14, 109 (2016)","journal-title":"Health Qual Life Outcomes"},{"key":"1159_CR66","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S0140-6736(10)61198-1","volume":"376","author":"K Swedberg","year":"2010","unstructured":"Swedberg, K., Komajda, M., B\u00f6hm, M., et al.: Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. The Lancet 376, 875\u2013885 (2010)","journal-title":"The Lancet"},{"key":"1159_CR67","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/j.1524-4733.2008.00425.x","volume":"12","author":"A G\u00f6hler","year":"2009","unstructured":"G\u00f6hler, A., Geisler, B.P., Manne, J.M., et al.: Utility estimates for decision-analytic modeling in chronic heart failure\u2014health states based on New York heart association classes and number of rehospitalizations. Value Health 12, 185\u2013187 (2009)","journal-title":"Value Health"},{"key":"1159_CR68","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.1093\/eurheartj\/ehv319","volume":"36","author":"G Habib","year":"2015","unstructured":"Habib, G., Lancellotti, P., Antunes, M.J., et al.: 2015 ESC guidelines for the management of infective endocarditis: the task force for the management of infective endocarditis of the European Society of Cardiology (ESC) endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). Eur. Heart J. 36, 3075\u20133128 (2015)","journal-title":"Eur. Heart J."}],"container-title":["The European Journal of Health Economics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10198-020-01159-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10198-020-01159-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10198-020-01159-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T18:26:09Z","timestamp":1722363969000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10198-020-01159-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,25]]},"references-count":68,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["1159"],"URL":"https:\/\/doi.org\/10.1007\/s10198-020-01159-y","relation":{},"ISSN":["1618-7598","1618-7601"],"issn-type":[{"value":"1618-7598","type":"print"},{"value":"1618-7601","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,25]]},"assertion":[{"value":"13 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}